Q-omics provides the consensus-scored SRSF12 profile across patient tissues and cancer cell-line models. SRSF12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in PAAD. Among the 18 cancer types available for tumor–normal comparison, SRSF12 is differentially expressed in 15, with the highest sampling consensus in KICH. Additionally, SRSF12 RNA expression shows 20,253 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight PAAD, KICH, and UVM as cancer lineages where SRSF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SRSF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SRSF12 survival associations across molecular data types. SRSF12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SRSF12 RNA expression–survival associations across cancer types. High SRSF12 expression shows unfavorable associations in KIRP, LIHC and BLCA, but favorable associations in PAAD, UCS and LAML. The PAAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify PAAD as the clearest survival context for SRSF12 RNA expression.
This table summarizes SRSF12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 1. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SRSF12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SRSF12 shows lower tumor expression in KICH and higher tumor expression in LUAD, KIRP, LUSC, LIHC and UCEC. The KICH box plot shows higher SRSF12 RNA expression in normal versus tumor tissue (log2 FC = −1.970, t-test p < 0.001).
This table shows molecular features associated with SRSF12 in patient tissues and cancer cell lines. In patient samples, SRSF12 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, SRSF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in BONE and UPPER_AERODIGESTIVE_TRACT.
